Literature DB >> 24714787

Misinterpretation of TPMT by a DTC genetic testing company.

C A Brownstein1, D M Margulies1, S F Manzi1.   

Abstract

23andme has suspended marketing of health-related reports due to US Food and Drug Administration approval violations. This has fostered discussions on the actual risks associated with consumer use of these reports. In the case described below, rare genotypes for the gene encoding thiopurine methyltransferase (TPMT) were misinterpreted by a direct-to-consumer (DTC) company, and risk calculations for breast cancer were offered when accuracy was not possible from the available information. Politics aside, these examples illustrate risks associated with DTC genetic testing without professional interpretation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24714787     DOI: 10.1038/clpt.2014.60

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Ethical considerations in genomic testing for hematologic disorders.

Authors:  Jonathan M Marron; Steven Joffe
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

2.  Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course.

Authors:  Kristin Wiisanen Weitzel; Caitrin W McDonough; Amanda R Elsey; Benjamin Burkley; Larisa H Cavallari; Julie A Johnson
Journal:  Am J Pharm Educ       Date:  2016-09-25       Impact factor: 2.047

3.  The audacity of interpretation: Protecting patients or piling on?

Authors:  Misha Angrist
Journal:  Appl Transl Genom       Date:  2014-09-01

4.  Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes.

Authors:  Ron Ammar; Tara A Paton; Dax Torti; Adam Shlien; Gary D Bader
Journal:  F1000Res       Date:  2015-01-21

Review 5.  Internet-Based Direct-to-Consumer Genetic Testing: A Systematic Review.

Authors:  Loredana Covolo; Sara Rubinelli; Elisabetta Ceretti; Umberto Gelatti
Journal:  J Med Internet Res       Date:  2015-12-14       Impact factor: 5.428

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.